Stay updated on Switch Maintenance in Pancreatic Clinical Trial

Sign up to get notified when there's something new on the Switch Maintenance in Pancreatic Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Switch Maintenance in Pancreatic Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed Revision: v3.4.1 and the government funding lapse notice.
    Difference
    0.4%
    Check dated 2026-02-11T11:24:49.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added a site-wide notice about government funding lapse and NIH operations status, and updated the page revision to v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T06:53:43.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a glossary toggle and new metadata fields such as Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and a version label Revision: v3.4.0. Removed the older labels Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.
    Difference
    0.3%
    Check dated 2026-01-28T04:23:42.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    New entries show 'Efficacy concerns' and 'Suspended' with dates 2026-01-14 and 2026-01-15, signaling a change in trial status. The Recruiting status and the principal investigator's contact information (email and phone) have been removed.
    Difference
    1.0%
    Check dated 2026-01-21T02:40:13.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    Minor site revision updated from v3.3.3 to v3.3.4; this change does not affect study details, eligibility criteria, or page navigation. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T02:07:52.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    The study record was revised to Phase Ib Open-Label, Multicenter, non-randomized design evaluating switch maintenance using AB154, AB122, and Sotigalimab in metastatic pancreatic cancer, with Massachusetts as a participating location. Eligibility criteria were updated to exclude germline BRCA mutations, and endpoints now include PFS2.
    Difference
    1%
    Check dated 2025-12-23T10:10:12.000Z thumbnail image

Stay in the know with updates to Switch Maintenance in Pancreatic Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Switch Maintenance in Pancreatic Clinical Trial page.